![]() |
市场调查报告书
商品编码
1792427
2025 年至 2033 年尼古丁口香糖市场报告(按类型、应用、配销通路和地区)Nicotine Gum Market Report by Type, Application, Distribution Channel, and Region 2025-2033 |
2024年,全球尼古丁口香糖市场规模达17亿美元。展望未来, IMARC Group预计到2033年,该市场规模将达到25亿美元,2025-2033年期间的复合年增长率(CAGR)为4%。推动全球市场成长的因素有很多,包括戒烟倡议、健康意识的增强,以及对便捷的非处方(OTC)尼古丁替代疗法的需求不断增长。提升产品功效的技术创新也为市场带来了显着的价值。
戒烟倡议和健康意识
全球范围内的吸烟减少措施以及健康意识的不断增强,正在推动市场扩张。随着人们对吸烟相关健康风险的认识不断提高,人们正在积极寻找有效的戒烟策略。尼古丁口香糖是一种戒烟辅助工具,它透过逐渐且可控地释放尼古丁来帮助使用者控制戒断症状。此外,由医疗机构和监管机构推出的各种戒烟计画也为尼古丁口香糖的需求创造了良好的环境。由于大众对健康的重视以及持续的禁烟努力,这种口香糖作为戒烟治疗的重要组成部分越来越受到人们的认可,这推动了市场的成长。 2023年4月11日,卫生部长尼尔·奥布莱恩在政策交流会上发表演讲,介绍了政府降低吸烟率和打击未成年人吸电子烟的计画。
非处方尼古丁替代疗法的需求不断增长
根据IMARC Group的数据,2023 年全球非处方药产业规模为 1,687 亿美元。推动市场发展的主要因素之一是对非处方尼古丁替代药物的需求不断增长。这种口香糖是一种易于取得的非处方解决方案,使用者无需处方即可自行治疗。对于想要戒烟而又不想寻求医疗协助的人来说,这种口香糖之所以受欢迎,是因为它易于取得且使用方便。人们在管理健康方面变得更加积极主动,这为尼古丁口香糖市场前景提供了积极的推动力。此外,2024 年 1 月 24 日,戒烟工作取得了重大突破,在奥里萨邦克塔克的 Sri Ram Chandra Bhanja (SCB) 牙科学院和医院进行的一项临床试验表明,尼古丁替代疗法 (NRT) 与行为疗法相结合具有显着的疗效。
技术进步与产品创新
尼古丁替代疗法配方和管理方面的持续技术改进和产品创新正在推动市场成长。尼古丁口香糖公司正在投入大量资金进行研发 (R&D) 活动,以提高产品的效能和使用者体验。使用者之所以接受这些口香糖,是因为其具有增强的口味和独特的输送系统等创新功能。此外,对尼古丁成瘾和戒断过程的深入了解也有助于开发更有效的口香糖配方。对更有效的戒烟解决方案日益增长的需求正在推动尼古丁口香糖市场的成长。除此之外,市场上的公司正在获得公认机构的产品批准。例如,Perrigo Company plc (PRGO) 于 2023 年 5 月 16 日获得了美国食品药物管理局 (FDA) 的最终批准,可生产 2 毫克和 4 毫克的尼古丁包衣薄荷味 OTC 含片。该产品有助于减轻试图戒烟的消费者的戒断症状。此外,它将以零售商商店品牌标籤进行销售,作为与 Nicorette 涂层冰薄荷糖类似的产品。
对于那些希望在戒烟过程中减少尼古丁摄取的人来说,2毫克尼古丁口香糖是个合适的选择。 2毫克尼古丁口香糖是控制戒断症状并逐步摆脱尼古丁依赖的理想替代品,是轻度至中度吸烟者的理想选择。此外,它还建议需要逐步戒断策略和戒烟初期的人士使用,以便更规律地过渡到无尼古丁的生活。
医疗实践占据行业最大份额
尼古丁口香糖在医疗环境中用于更全面的戒烟计划。医生可能会将这种口香糖推荐给患者,作为个人化戒烟方案的一部分,或在常规咨询中服用。口香糖中尼古丁的渐进式和调节性释放与实证疗法相符。在医疗实践应用中,强调了医疗保健专业人员在帮助人们戒烟方面的重要性,以及使用尼古丁口香糖带来的健康益处和个人化帮助。
零售药局是主要的细分市场
尼古丁口香糖在零售药局很容易买到。寻找戒烟产品的消费者可以轻鬆地在家附近找到它们。这种口香糖很容易买到,药剂师也可以提供相关的用药建议,这使得它成为那些寻求面对面支持和快速获得戒烟产品的人的首选。
北美领先市场,占据尼古丁口香糖最大市场份额
该报告还对所有主要区域市场进行了全面分析,包括北美(美国和加拿大);亚太地区(中国、日本、印度、韩国、澳洲、印尼等);欧洲(德国、法国、英国、义大利、西班牙、俄罗斯等);拉丁美洲(巴西、墨西哥等);以及中东和非洲。报告指出,北美是尼古丁口香糖最大的区域市场。
北美凭藉其强大的戒烟力度、日益增强的健康意识以及庞大的消费者群体,成为重要的市场。该地区拥有完善的医疗基础设施和积极的监管措施,这些因素促使尼古丁口香糖成为首选的戒烟辅助工具。此外,在北美地区,寻求有效戒烟解决方案的人数也不断增加。此外,尼古丁口香糖在零售药局和线上商店等各种分销管道的广泛供应也有助于增加尼古丁口香糖市场的收入。 2024年3月18日,全球领先的合约开发和製造组织 (CDMO) Cambrex 宣布完成一项为期5年、总额达1亿美元的投资策略,比原计划提前一年完成。该项目将为其北美和欧洲 70% 的药物开发和製造网络增加超过 150,000 平方英尺的产能和能力扩展,并将于 2024 年底完成。投资涵盖所有规模的临床和商业药物物质製造,并包括解决与复杂分子相关的挑战的先进技术。
The global nicotine gum market size reached USD 1.7 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 2.5 Billion by 2033, exhibiting a growth rate (CAGR) of 4% during 2025-2033. There are various factors that are responsible for the growth of the global market, which include smoking cessation initiatives and heightened health awareness, rising demand for convenient over the counter (OTC) nicotine replacement therapies. Technological innovations for enhancing product efficacy also add significant value to the market.
Smoking Cessation Initiatives and Health Awareness
Global efforts to reduce smoking, along with rising health awareness, are propelling the market expansion. People are actively looking for effective strategies to quit smoking as awareness about health risks connected with smoking increases among them. Nicotine gum is a smoking cessation aid that helps users manage the symptoms of withdrawal by releasing nicotine gradually and under control. In addition, various smoking cessation programs by healthcare organizations and regulatory authorities has created a favorable atmosphere for nicotine gum demand. The rising acceptance of this gum as an essential component of smoking cessation treatments due to the emphasis on public health and the ongoing efforts to eliminate smoking is impelling the market growth. On 11 April 2023, Neil O'Brien, Health Minister, delivered a speech at Policy Exchange on government plans to cut smoking rates and tackle underage vaping,
Growing Demand for OTC Nicotine Replacement Therapies
As per the IMARC Group, in 2023, the size of the OTC medication industry worldwide was US$ 168.7 Billion. One of the main factors propelling the market is the rising demand for OTC nicotine replacement medicines. This gum is an easily available OTC solution that enables users to self-administer therapy without a prescription. This gum's popularity as a top option for people trying to stop smoking without seeking medical help is due to its accessibility and ease of usage. People are becoming more proactive in managing their health, which is offering a positive nicotine gum market outlook. Furthermore, on 24 January 2024, in a significant breakthrough for tobacco cessation efforts, a clinical trial conducted at Sri Ram Chandra Bhanja (SCB) Dental College and Hospital in Cuttack, Odisha, unveiled the remarkable efficacy of nicotine replacement therapy (NRT) when combined with behavioral therapy.
Technological Advancements and Product Innovation
Continuous technological improvements and product innovations in the formulation and administration of nicotine replacement therapies are bolstering the market growth. Nicotine gum companies are spending money on research and development (R&D) activities to enhance the effectiveness of product as well as user experience. Users are adopting these gums owing to innovations like enhanced flavors and unique delivery systems. In addition, enhanced understanding of nicotine addiction and withdrawal processes are benefiting in the creation of gum formulations that are more efficient. The escalating demand for more efficient smoking cessation solutions is bolstering the nicotine gum market growth. Besides this, companies in the market are getting product approvals from the recognized authorities. For instance, Perrigo Company plc (PRGO) received final approval from the Food Drug Administration (FDA) for nicotine coated mint lozenges 2 mg and 4 mg OTC on 16 May 2023. The product helps in reducing withdrawal symptoms in consumers who are trying to quit smoking. Moreover, it will be marketed under retailer's store brand labels as a comparable offering to Nicorette coated ice mint lozenge.
Those looking to cut back on their nicotine intake during their journey to quit smoking can find 2 mg category a suitable choice. 2mg nicotine gum is an ideal alternative for controlling withdrawal symptoms while progressively weaning off nicotine dependence, making it the perfect choice among light to moderate smokers. Furthermore, it is advised for people who need a step-down strategy and in the early phases of quitting in order to enable a more regulated shift to a life free of nicotine.
Medical practice holds the largest share of the industry
Nicotine gums are used in more comprehensive smoking cessation programs in medical settings. Physicians may recommend this gum to patients as part of individualized smoking cessation regimens or during routine consultations. The progressive and regulated release of nicotine from the gum is consistent with evidence-based therapies. In the medical practice application, the importance of healthcare professionals in helping people quit is emphasized, along with the health advantages and individualized assistance that come with using nicotine gum.
Retail pharmacies represent the leading market segment
Nicotine gums are readily available at retail pharmacies. Consumers in search of smoking cessation products can easily locate them in close proximity to their homes. This gum is easily available and pharmacists can offer their advice related to medication, which makes it a favored option for those seeking person-to-person support and quick access to quit smoking products.
North America leads the market, accounting for the largest nicotine gum market share
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America represents the largest regional market for nicotine gum.
North America stands as a significant market due to robust smoking cessation efforts, heightened health awareness, and a substantial consumer base. The region has a well-established healthcare infrastructure and proactive regulatory measures that contribute to the popularity of these gums as a preferred smoking cessation aid. In addition, there is an increase in the number of individuals seeking effective solutions to quit smoking in the North America region. Besides this, the wide availability of these gum across various distribution channels including retail pharmacies and online stores, assists in increasing nicotine gum market revenue. On 18 March 2024, Cambrex, a leading global contract development and manufacturing organization (CDMO), announced the completion of a 5-year, US$ 100-Million-dollar investment strategy, one year ahead of schedule. The project adds more than 150,000 square-feet of capacity and capability expansions across 70% of its North American and European drug development and manufacturing network, which will be completed by the end of 2024. The investments span all scales of clinical and commercial drug substance manufacturing and include advanced technologies to solve for challenges related to complex molecules.